Figure 3From: Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis Indirect comparisons for overall survival: HRs and 95% CIs for various treatment comparisons. Horizontal: Experimental vs. Control; Vertical: Control vs. Experimental. HR < 1 indicates OS or PFS benefit. *Hazard ratios are statistically significant. Gem = gemcitabine; 5FU = 5-flurouacil; PEFG = gemcitabine + epirubicin + 5FU + cisplatin; NAB-P = NAB-P; bev = bevacizumab; erlo = erlotinib; cape = capecitabine; oxali = oxaliplatin; tipif = tipifarnib; pem = pemetrexed; cis = cisplatin; irino = irinotecan; FA = folinic acid; cetux = cetuximab; soraf = sorafenib. Back to article page